Incyte Corp (NASDAQ:INCY)
| 78.06 Delayed Data As of 4:34pm ET |  -2.28 / -2.84%Today’s Change | 62.48 Today|||52-Week Range 110.37 | -10.26% Year-to-Date |
Latest INCY News | Press Releases
| Lilly (LLY) COVID-19 Antibody Bamlanivimab Gets CHMP Nod 9:25am / Zacks.com - Paid Partner Content | The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Incyte, Nektar Therapeutics, Immunome and Otonomy Feb 25 / Zacks.com - Paid Partner Content |
| Biotech Stock Roundup: REGN, VIR's COVID-19 Updates, KMPH's Drug Approval & More Mar 04 / Zacks.com - Paid Partner Content | Biotech Stock Roundup: Regulatory Updates From REGN, INCY, & Other Updates Feb 24 / Zacks.com - Paid Partner Content |
| Acceleron (XLRN) Q4 Loss Wider Than Expected, Revenues Beat Mar 01 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 80.34 |
| Today’s open | 79.83 |
| Day’s range | 77.75 - 80.94 |
| Volume | 62,816 |
| Average volume (3 months) | 1,228,226 |
| Market cap | $17.6B |
Data as of 4:34pm ET, 03/08/2021
Growth & Valuation
| Earnings growth (last year) | -165.21% |
| Earnings growth (this year) | +277.45% |
| Earnings growth (next 5 years) | +83.56% |
| Revenue growth (last year) | +23.53% |
| P/E ratio | NM |
| Price/Sales | 7.11 |
| Price/Book | 6.75 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| CTLTCatalent Inc | -2.97 | -2.84% |
| VTRSViatris Inc | -0.14 | -1.00% |
| ALNYAlnylam Pharmaceutic... | -4.86 | -3.39% |
| HZNPHorizon Therapeutics... | -2.03 | -2.29% |
Data as of 4:39pm ET, 03/08/2021
Financials
| Next reporting date | May 4, 2021 |
| EPS forecast (this quarter) | $0.45 |
| Annual revenue (last year) | $2.7B |
| Annual profit (last year) | -$295.7M |
| Net profit margin | -11.09% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Wilmington, Delaware |
Forecasts
